Skip to content

Exercise-induced Ischemia and the Influence of Pain Modulation in a Nerve Growth Factor (NGF) Model

Interaction Between NGF and Exercise-induced Ischemia, and the Influence of the Pain Modulating System in a Prolonged NGF Sensitized Muscle.

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03844243
Enrollment
20
Registered
2019-02-18
Start date
2019-02-18
Completion date
2019-06-30
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects, Hyperalgesia, Pain Response

Keywords

NGF-induced hyperalgesia, Exercise-induced ischemic pain, Pain modulation, NGF pain model

Brief summary

The purpose of this study is to investigate responses of pain and the maintenance of mechanical muscle hypersensitivity following an acute exercise-induced ischemic condition repeated over time in a prolonged NGF-sensitized muscle. Additionally, the influence of the pain modulating system on prolonged NGF muscle hypersensitivity caused by peripheral mechanisms and central mechanisms will also be investigated.

Detailed description

The hypothesis is that an ischemic conditioning in a NGF-sensitized muscle is able to facilitate pain responses and that over time the pain modulation system is responsible for a subsequent reduction in muscle sensitivity towards mechanical pressure and a decrease in pain intensity following a period of NGF-induced muscle hypersensitivity.

Interventions

DRUGNGF

Intramuscular injection

DRUGIsotonic-saline

Intramuscular injection

Sponsors

Aalborg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Double-blinded

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy and pain free volunteers

Exclusion criteria

* Pregnancy * Drug addiction defined as the use of cannabis, opioids or other drugs * Previous neurologic, mental illnesses, or psychiatric diseases. * Past history of chronic pain in the musculoskeletal system (muscle, joint, cartilage, connective tissue) * Participation in other pain trials throughout the study period * Lack of ability to cooperate * Taking any analgesic 24 hours before the injections * Performing any strenuous leg exercise through out the study period causing sore muscles

Design outcomes

Primary

MeasureTime frameDescription
Muscle pain sensitivity (PPTs values) assessed by pressure algometerChange from baseline at 3 weekPressure pain thresholds (PPTs) are assessed over the dominant tibialis anterior muscle using a handhold pressure algometer.

Secondary

MeasureTime frameDescription
Ischemic-induced pain intensityAssessed right after the exercise has been performed, change from baseline at 3 weeksSubjects perform a repeated static exercise with their dominant leg while a cuff is mounted over the knee to occlude the blodflow from the muscle (ischemia). Subjects subsequently rate their perceived pain intensity verbally on a 11-point numeric rating scale (NRS) rating from 0 (no pain) to 10 (worst pain imaginable).
Functional muscle painChange from baseline at 3 weeksSubjects evaluate their muscle pain during movement using a 7-point Likert Scale for lower limp rating from 0 (a complete absence of pain) to 6 (a severe pain that limits my ability to move).
Conditioning pain modulation (CPM) efficacyChange from baseline at 3 weeksA test stimuli will be applied and compared with a test stimuli simultaneous a condition stimuli.
Temporal summation of painChange from baseline at 3 weeks10 repeated stimuli will be applied and subjects will be asked to rate the pain for each individual stimuli on a 11-point visual analogue scale (VAS) rating from 0 (no pain) to 10 (worst pain imaginable)

Countries

Denmark

Contacts

Primary ContactLine Bay Sørensen, PhD. stud.
lbs@hst.aau.dk52373229

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026